Journal of Bioequivalence & Bioavailability

BIOEQUIVALENCE TESTINGINDUSTRY PERSPECTIVE

International Conference & Exhibition Bioequivalence and Bioavailability

March 01-03,2010

A.T. Bapuji

Scientific Tracks Abstracts: J Bioequiv Availab 2010

Abstract:

T he assessment of the bioequivalence of topical products not intended for absorption into the systemic circulation has presented a formidable challenge over the years. In particular, dermatological dosage forms such as creams, ointments, lotions and gels, apart from those containing topical corticosteroids, cannot readily be assessed for bioequivalence using ?conventional? methodology and the only recourse to-date has been to undertake tedious, time consuming and expensive clinical end-point trials for such products. Although the human skin blanching assay (HSBA), also known as the vasoconstriction assay (VCA) has been successfully used for dermatological products containing topical corticosteroids and the methodology has found formal acceptance by a number of regulatory agencies, e.g. the US FDA amongst others, no surrogate methodology for the bioequivalence assessment of other topical dermatological products such as those containing non- steroidal anti-inflammatory drugs, anti-fungals, antibiotics and antivirals has yet found favour with regulatory agencies. Application of the HSBA, Tape Stripping (TS) and Dermal Microdialysis (DMD) for the assessment of bioequivalence will be described and the theoretical basis and prognosis for each technique will be discussed.